Mark Carey


Mark Carey

M.D., F.R.C.S.C.

Clinical Professor

Division of Gynaecologic Oncology

Portrait photo of Mark Carey

Vancouver Coastal Health (VCH)

Vancouver General Hospital

: 6048754268




Research Interests/Skills



  1. Mert I, Chhina J, Ghassan A., Jing D, Seward S, Carey MS, Llaurado M, Giri S, Rattan R. Synergistic effects of MEK inhibitor and metformin in low-grade serous ovarian cancer, Gynecol Oncol. Aug; 146920: 319-326, 2017
  2. Kwon JS, Pansegrau G, Nourmoussavi M, Hammond G, Carey MS, Costs and benefits of extended endocrine strategies for premenopausal breast cancer. Journal of National Comprehensive Cancer Network. 15.8: 1015-1021, 2017
  3. Nourmoussavi M, Panesgrau G, Popesku J, Hammond GL, Kwon MS, Carey MS. Ovarian ablation for premoenopausal breast cancer: A review of treatment considerations and the impact of premature meneopause. Cancer Treatment Rev, 55:26-35, 2017
  4. Llaurado M, DiMattia G, Dawson A,  Bamford S, Hennessy B,  Angelesi, MS, Shepherd T, Salamanca C, Tinker A, Huntsman D, Carey, MS. Evaluation of MEK Inhibitors in molecularly characterized lo-grade serous ovarian cnacer cells. Am J Cancer Res. Oct 1;6(10):2235-2251, 2016 
  5. Kwon JS, Pansegrau G, Nourmoussavi M, Hammond GH, Carey MS. Long-term consequences of ovarian ablation for premenopausal breast cancer: Breast Cancer Res Treat 157(3): 565-73, 2016
  6. Stamp JP, Gilks CB, Wesseling M, Eshragh S, Ceballos K, Anglesio MS, Kwon JS, Tone A, Huntsman DG, Carey MS. BAF250a Expression in Atypical Endometriosis and Endometriosis-associated Ovarian Cancer. International Journal of Gynecological Cancer 26(5): 825-32, 2016.
  7. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M , Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ,      ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. The Lancet Oncology 16(8): 928-36, 2015.
  8. Kwon JS, McGahan C, Dehaeck U, Santos J, Swenerton K, Carey MS.  The significance of combination chemotherapy in epithelial ovarian cancer. International Journal of Gynecological Cancer 24(2): 226-32, 2014.
  9. Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS. A Functional Proteogenomic Analysis of Endometrioid and Clear Cell Carcinomas using Reverse Phase Protein Array and Mutation Analysis: Protein Expression is Histotype-specific and Loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC cancer 14.1: 120, 2014
  10. Llauradó M, Majem B, Altadill T, Lanau L, Castellví J, Sánchez-Iglesias JL, Cabrera S, Díaz-Feijoo B,        Pérez-Benavente A, Colás E, Olivan M, Doll A, Alameda F, Matias-Guiu X, Moreno-Bueno G, Carey MS, Del Campo JM, Gil-Moreno A, Reventós J, Rigau M. MicroRNAs as prognostic markers in ovarian cancer. Molecular and Cellular Endocrinology 390(1-2): 73-84, 2014.
  11. Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J,    Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O’Leary JJ, Mills GB, Hennessy BT. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Molecular oncology 7(3): 567-79, 2013.
  12. Dehaeck U, McGahan CE, Santos JL, Carey MS, Swenerton KD, Kwon JS. The Impact of Geographic Variations in Treatment on Outcomes in Ovarian Cancer. Int J Gynecol Cancer 23(2):282-7, 2013.
  13. Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A,Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AMOza A, Perren T. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. The Lancet Oncology 14(3): 236-43, 2013
  14. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS. Patterns of Genomic Loss of Heterozygosity Predict Homologous Recombination Repair Defects in Epithelial Ovarian Cancer. Br J Cancer 107(10):1776-82, 2012.
  15. Russel P, Hennessy BT, Li J, Carey MS, Bast RC, Freeman T, Venkitaraman.  Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest. Oncogene 31(19);2450-60, 2012.
  16. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A., Kurzeder, C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W PhD, Parmar MKB, Oza A. Bevacizumab in Ovarian Cancer: ICON7- A Phase III Gynecologic Cancer InterGroup Trial. New England Journal of Medicine 365(26):2484-96. Dec 29, 2011.
  17. Nieman KM, Kenny HA, Ladanyi A, Penicka C, Buell-Gutbrod R, Carey MS, Zillhardt MR, Hotamisligil G, Mills GM,  Haney AF, Yamada SD,  Peter ME, Gwin K, Lengyel E. Adipocytes promote ovarian cancer metastasis and provide the energy for rapid tumor growth. Nature Medicine 17(11):498-503, 2011.
  18. Gonzalez-Angulo AM, Hennessy BY, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Lei D, Broaddus R, Lluch AM, Aparicio S, Brown P, Pusztai L, Symmans F, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 8(1):11, 2011.
  19. Carey MS, Gotay C. Patient-Reported Outcomes: Clinical Trials in Ovarian Cancer. Int J Gynecol Cancer 21: 782-787, 2011.
  20. Anglesio MS, Carey MS, Köbel M, MacKay H, Vancouver Ovarian Clear Cell Symposium Speakers, Huntsman DG. Cell Carcinoma of the Ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gyn Onc 121(2):407-15, 2011.


2017-2018                    Developing a nation-wide research network for the study of rare cancers: The example of Low-grade serous ovarian cancer. CIHR Planning and Dissemination Grant – The Institute of Community Support. Funding $10,000, PI: Dr. MS Carey


2016-2017                     In-vitro testing of Cantrixil in Ovarian Cancer Cell Lines. Industry sponsored research (Novogen). Funding $70,000.  PI: Dr. MS Carey


2016 – 2018                   Exploring the proteo-genomic profiles of low-grade serous cancers to investigate MEK inhibitor response.  Carraresi Foundation OvCaRe Research Grant, VGH and UBC Hospital Foundations.  Internal Grant Competition.  Funding $20,000.  PI: Dr. MS Carey


2014 – 2017                  Low-grade serous ovarian cancer project grant.  BC Cancer Foundation. $100,000. PI: Dr MS Carey


2013 – 2017                  Contextual Genomics: The foundation for subtype-specific approaches to ovarian cancer control.  Canadian Cancer Society Research Institute.   Funding $1,250,000.  Co-investigator, PI: Dr. David Huntsman


2005 – 2008                  Development of Health Informatics Unit for the Women’s, Children’s and Oncology Programs at the University of Western Ontario, Academic Medical Organizations of Southwestern Ontario, $225,000, PI: Dr. MS Carey

2003 – 2005                  PET/CT for endometrial cancer, Academic Enrichment Fund, Department of Obstetrics and Gynecology, University of Western Ontario, $7,500, Co-investigator, PI: Dr. JS Kwon

2002 – 2003                  Sentinel node mapping in endometrial cancer:  A pilot study, Internal Research Fund, Lawson Health Research Institute, $7,500, Co-investigator, PI: Dr. J Kwon